The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cycloset
(United States) [Available] ,Parlodel
(United States) [Available]Synonyms :
bromocriptine
Class :
Dopamine Agonists
Dosage forms and strengths
Tablet-Parlodel
2.5mg
Capsule-Parlodel
5mg
Tablet-Cycloset
0.8mg
1.25 - 2.5
mg
Orally
once a day
dose can be increased up to 2.5 mg every 2 to 7 days
Maintenance dose: 2.5-15 mg orally once a day
Initial dose:
1,25 - 2.5
mg
Orally
once a day
dose can be increased up to 1.25 to 2.5 mg as tolerated every 3 to 7 days
Maintenance dose: 20 to 30 mg once a day
Maximum dose: 100 mg once a day
Initial dose:
1.25
mg
Orally
twice a day
dose can be increased up to 2.5 mg per day every 14 to 28 days
Maximum dosage: 100 mg once a day
Initial dose:
0.8
mg
Orally
once a day
Maintenance dose: 1.6-4.8 mg orally once a day
The duration of therapy is 4.8 mg per day
Dosage forms and strengths
Tablet-Parlodel
2.5mg
Capsule-Parlodel
5mg
Age: 11-15 years
initial:
1.25 - 2.5
mg
Orally
once a day
may increase the hypertension effect
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increased hypertensive effect when combined with alpha1-blockers
bunazosin (Not available in the United States)
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha-/beta-agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may increase the hypertensive effect of Alpha2-Agonists
may increase the hypertension effect of alfa one agonist
may increase the hypertension effect of alfa one agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may increase the hypotensive effects of alpha/beta agonists
may enhance the serum concentration of CYP3A4 inhibitors
acrivastine and pseudoephedrine
may increase the hypertensive effect of alpha/beta agonists
may increase the adverse effect of Serotonin 5-HT1D Receptor Agonists
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the hypertensive effect of Alpha-/Beta-Agonists
may enhance the risk of hypoglycemia when combined with Bromocriptine
may have an increased risk of hypoglycemia when combined with bromocriptine
may enhance the serum concentration of CYP3A4 Inhibitors
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
ergot derivatives increase the toxicity of bromocriptine
ergot derivatives increase the toxicity of bromocriptine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromocriptine
may increase the risk or severity of adverse effects when combined
may increase the toxic effect of ergot derivatives
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
dopamine agonists' efficacy will decrease when metoclopramide is used in combination
the efficacy of dopamine agonists will be decreased when sulpride is used in combination
When medrysone is used in conjunction with bromocriptine, the risk or seriousness of hyperglycemia can rise
The potential for increased CNS depression risk or seriousness occurs when bromocriptine is used together with pinazepam
The potential for increased CNS depression risk or seriousness occurs when bromocriptine is used together with pipecuronium
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
When bromocriptine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with bromocriptine, There is a risk or seriousness of CNS depression is enhanced
When bromocriptine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when bromocriptine is used together with fencamfamin
When bromocriptine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When alprazolam and bromocriptine is used together, this leads to reduction in the alprazolam’s metabolism
When chlordiazepoxide is used together with bromocriptine, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with bromocriptine, this leads to enhanced risk or seriousness of CNS depression
When bromocriptine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
combining ipratropium and bromocriptine may enhance the incidence or severity of tachycardia
When bromocriptine is used together with oleandomycin, this leads to enhanced concentration serum of bromocriptine
When bromocriptine is used together with patupilone, this leads to enhanced concentration serum of bromocriptine
When bromocriptine is used together with ridaforolimus, this leads to enhanced concentration serum of bromocriptine
bromocriptine: it may increase the risk of CNS depression with pridinol
bromocriptine: it may increase the central nervous system depressant activities of tolperisone
When helometasone is used together with bromocriptine, this leads to elevated risk or seriousness of hyperglycemia
When bromocriptine is used together with diazoxide, this leads to reduction in therapeutic effectiveness of bromocriptine
methylprednisolone hemisuccinate
When methylprednisolone hemisuccinate is aided with bromocriptine, this leads to elevated hyperglycemia risk
the effect of bromocriptine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
domperidone decreases the effect of bromocriptine
may enhance the risk of hypertension when combined with bromocriptine
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
the side effects of dopamine agonists are increased with bromopride when combined
side effects of bupropion are increased when dopamine agonist is combined
side effects of dopamine agonists are increased with solriamfetol when combined
the therapeutic effects of bromocriptine may be reduced
the risk of hyperglycemia may be increased
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
Actions and Spectrum:
It is dopamine receptor agonist, which stimulates dopamine receptors mainly D2 subtype present on the cells within the CNS.
Stimulates dopamine receptors and thus suppresses prolactin secretion from the pituitary gland.
This drug has an impact on the dopamine receptors that can be useful in the treatment of disorders, which are related to dopamine deficit or prolactin elevation.
As a result, its spectrum of activity includes endocrine, neurological and metabolic diseases accompanying alterations of dopamine receptors.
Frequency defined:
>10%
Cycloset
Monotherapy
Dizziness (12.5%)
Asthenia (12.5%)
Headache (12.5%)
Rhinitis (13.8%)
Nausea (32.5 %)
Adjunct to sulfonylurea
Rhinitis (10.7%)
Dizziness (11.9%)
Headache (16.8%)
Asthenia (18.9%)
Nausea (25.4%)
1-10%
Cycloset
Monotherapy
Vomiting (6.3%)
Dyspepsia (7.5%)
Amblyopia (7.5%)
Diarrhea (8.8%)
Sinusitis (10%)
Adjunct to sulfonylurea
Somnolence (6.6%)
Sinusitis (7.4%)
Cold (8.2%)
Flu syndrome (9.4%)
Constipation (9.8%)
Parlodel
Hyperprolactinemic indications
Nasal congestion (3%)
Abdominal cramps (4%)
Vomiting (5%)
Fatigue (7%)
Black Box Warning:
None
Contraindication/Caution:
Pregnancy and postpartum hypertension
Hypersensitivity
Uncontrolled hypertension
Cardiovascular disease
Severe psychiatric disorders
Pregnancy/Lactation:
Pregnancy warnings:
AU TGA pregnancy category: A
US FDA pregnancy category: B
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy category:
Pharmacology:
Bromocriptine is a semisynthetic derivative of ergot of the alkaloid classification. They are utilised in numerous clinical setting due to modulating impact on the dopaminergic system.
Pharmacodynamics:
Dopamine D2 Agonism: The drug bromocriptine is most selective for D2 receptors, and this led to suppression of the prolactin hormone secretion by the gland. This makes it useful in such conditions as hyperprolactinemia and prolactinomas as well as other diseases.
Inhibition of Prolactin Secretion: It inhibits the secretion of prolactin, and it is used in conditions like, galactorrhea and female infertility caused by excessive prolactin.
Pharmacokinetics:
Absorption
Following oral administration, the drug is rapidly and well absorbed, and the plasma concentration reaches its maximum level after 1-2 hours of the intake.
Distribution
It is very protein bound (about 90-96 %) and it distributes in the tissues and the CNS.
Metabolism
Bromocriptine is metabolized in the liver by the cytochrome P450 system, primarily CYP3A4.
Excretion and Elimination
The drug and its metabolites are primarily excreted via the urine (2 to 6 %) and feces, (82%). The half-life for parlodel is approximately 4.85 hours and for cycloset it is approximately 6 hours.
Administration:
The drug is taken orally with food.
Patient information leaflet
Generic Name: bromocriptine
Pronounced: BROE-moe-KRIP-teen
Why do we use bromocriptine?
Bromocriptine is an anti-parkinsonism drug belonging to the subclass Dopamine agonist used to treat Parkinson’s disease, hyperprolactinemia and control high blood sugar.
Parkinson’s disease: To control the symptoms as it activates dopamine receptors.
Hyperprolactinaemia: For decreasing high levels of prolactin in the blood which in turn cause amenorrhea, oligomenorrhoea, anovulation and galactorrhea in non-lactating women.
Acromegaly: To decrease the secretion of growth hormone.
Type 2 diabetes: As an adjunct to improve glycemic control.
Prolactinomas: To reducing the size of the tumor that secretes too much of the hormone prolactin.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
